Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)

Eur J Haematol. 2021 Sep;107(3):370-373. doi: 10.1111/ejh.13667. Epub 2021 Jun 1.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Central Nervous System Neoplasms / drug therapy*
  • Central Nervous System Neoplasms / mortality
  • Central Nervous System Neoplasms / pathology
  • Female
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / mortality
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / pathology
  • Neoplasms, Second Primary / drug therapy*
  • Neoplasms, Second Primary / mortality
  • Neoplasms, Second Primary / pathology
  • Piperidines / therapeutic use*
  • Prognosis
  • Retrospective Studies
  • Survival Analysis
  • Temozolomide / therapeutic use*

Substances

  • Piperidines
  • ibrutinib
  • Adenine
  • Temozolomide